Hudson Bay Capital Management LP Decreases Stake in Arrowhead Pharmaceuticals, Inc. $ARWR

Hudson Bay Capital Management LP lessened its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 65.4% during the 3rd quarter, HoldingsChannel reports. The firm owned 90,000 shares of the biotechnology company’s stock after selling 170,000 shares during the period. Hudson Bay Capital Management LP’s holdings in Arrowhead Pharmaceuticals were worth $3,104,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. iSAM Funds UK Ltd acquired a new stake in shares of Arrowhead Pharmaceuticals in the third quarter valued at about $29,000. Salomon & Ludwin LLC acquired a new position in Arrowhead Pharmaceuticals during the third quarter worth about $34,000. Federated Hermes Inc. acquired a new position in Arrowhead Pharmaceuticals during the third quarter worth about $52,000. Smartleaf Asset Management LLC grew its stake in Arrowhead Pharmaceuticals by 2,186.5% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,692 shares of the biotechnology company’s stock valued at $57,000 after acquiring an additional 1,618 shares in the last quarter. Finally, Virtus Advisers LLC purchased a new stake in Arrowhead Pharmaceuticals during the 2nd quarter valued at about $34,000. Hedge funds and other institutional investors own 62.61% of the company’s stock.

Insiders Place Their Bets

In related news, COO Patrick O’brien sold 49,493 shares of the firm’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $63.11, for a total transaction of $3,123,503.23. Following the completion of the sale, the chief operating officer directly owned 474,908 shares of the company’s stock, valued at approximately $29,971,443.88. This trade represents a 9.44% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider James C. Hamilton sold 10,000 shares of the business’s stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $64.19, for a total transaction of $641,900.00. Following the completion of the sale, the insider owned 236,958 shares in the company, valued at approximately $15,210,334.02. This trade represents a 4.05% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 184,686 shares of company stock worth $12,136,118 over the last ninety days. Company insiders own 3.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. Piper Sandler reissued an “overweight” rating and issued a $110.00 target price (up from $100.00) on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, January 13th. Morgan Stanley upped their price target on Arrowhead Pharmaceuticals from $48.00 to $81.00 and gave the company an “equal weight” rating in a research report on Wednesday, January 7th. Weiss Ratings raised Arrowhead Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a report on Friday, February 6th. The Goldman Sachs Group lifted their price objective on Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 7th. Finally, B. Riley Financial boosted their price objective on Arrowhead Pharmaceuticals from $61.00 to $101.00 and gave the stock a “buy” rating in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $81.67.

Arrowhead Pharmaceuticals Stock Performance

Arrowhead Pharmaceuticals stock opened at $56.33 on Friday. The firm has a 50 day simple moving average of $63.57 and a 200-day simple moving average of $52.56. The stock has a market cap of $7.89 billion, a price-to-earnings ratio of 36.82 and a beta of 1.23. The company has a debt-to-equity ratio of 0.29, a current ratio of 3.38 and a quick ratio of 3.38. Arrowhead Pharmaceuticals, Inc. has a 1-year low of $9.57 and a 1-year high of $76.76.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings results on Thursday, February 5th. The biotechnology company reported $0.22 EPS for the quarter, missing the consensus estimate of $0.60 by ($0.38). Arrowhead Pharmaceuticals had a net margin of 18.54% and a return on equity of 35.64%. The firm had revenue of $264.03 million for the quarter, compared to analysts’ expectations of $225.66 million. During the same period in the previous year, the firm posted ($1.39) EPS. The firm’s quarterly revenue was up 10461.3% compared to the same quarter last year. On average, analysts expect that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.